Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chongqing Huiyuan Pharma Acquires Singapore Chinese Medicines And Health

This article was originally published in PharmAsia News

Executive Summary

Chongqing Huiyuan Pharma has recently completed the acquisition of Singapore's second-largest pharmaceutical retail chain company - Singapore Chinese Medicines and Health - with RMB 10 million ($1.46 million). Huiyuan will set up a large-scale one-stop TCM supermarket in Singapore that integrates diagnosis services by TCM physicians and sale of health products and Chinese herbal slices. The firm will also establish branches in Southeast Asia to develop TCM clinics, training, exhibition and wholesale businesses. The acquisition is set to boost sales of Chongqing-made Chinese crude medicines and herbal slices in the Singapore market, as well as enhance Chongqing city's TCM product expansion in Southeast Asia. (Click here for more - Chinese Language)

You may also be interested in...



A Stroke Of Luck Boosts Oxford/AZ’s “Vaccine For The World”

AstraZeneca's research head admits that half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.

Accelerating The Global Self-Care Agenda: Q&A With GSCF Chair, Bayer CH Head Heiko Schipper

HBW Insight speaks to new Global Self-Care Federation chair and Bayer CH chief Heiko Schipper about the role that self-care can play in alleviating pressure on national health care systems, the importance of self-care's scientific credentials and of maintaining supply chain continuity during the coronavirus pandemic.

Innovation-Friendly? Cases Indicate How Far China's Willing To Protect Patents

Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel